IFM Investors Pty Ltd Increases Position in Catalent, Inc. (NYSE:CTLT)

IFM Investors Pty Ltd boosted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 10.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,543 shares of the company’s stock after acquiring an additional 3,372 shares during the period. IFM Investors Pty Ltd’s holdings in Catalent were worth $2,006,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CTLT. Vanguard Group Inc. grew its stake in shares of Catalent by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after buying an additional 365,648 shares during the period. Capital World Investors grew its stake in shares of Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after buying an additional 1,098,474 shares during the period. Nomura Holdings Inc. grew its stake in shares of Catalent by 149.4% in the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after buying an additional 6,881,914 shares during the period. Cadian Capital Management LP boosted its position in shares of Catalent by 14.3% during the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares during the period. Finally, Barclays PLC boosted its position in shares of Catalent by 41.7% during the 3rd quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock worth $218,440,000 after purchasing an additional 1,412,058 shares during the period.

Wall Street Analyst Weigh In

CTLT has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of Catalent in a research report on Saturday. They set a “sell” rating for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. UBS Group reaffirmed a “neutral” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays increased their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Finally, Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $52.46.

Catalent Stock Up 0.2 %

Shares of CTLT traded up $0.12 during midday trading on Friday, reaching $55.92. The stock had a trading volume of 2,846,393 shares, compared to its average volume of 1,545,863. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $60.20. The company’s fifty day simple moving average is $56.68 and its two-hundred day simple moving average is $48.70. The company has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.03 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business posted $0.62 earnings per share. Catalent’s revenue for the quarter was down 10.2% compared to the same quarter last year. Equities research analysts expect that Catalent, Inc. will post 0.28 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.